Cytek Biosciences, Inc.
General ticker "CTKB" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $566.7M (TTM average)
Cytek Biosciences, Inc. follows the US Stock Market performance with the rate: 13.1%.
Estimated limits based on current volatility of 2.4%: low 5.16$, high 5.41$
Factors to consider:
- Total employees count: 648 (-4.1%) as of 2024
- US accounted for 46.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Product performance and technology reliability, Geopolitical risks, Vendor dependency, Regulatory and compliance, Strategic risks and growth management
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.15$, 8.35$]
- 2025-12-31 to 2026-12-31 estimated range: [3.92$, 7.98$]
Financial Metrics affecting the CTKB estimates:
- Negative: with PPE of -128.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of -1.19
- Positive: -14.38 < Investing cash flow per share per price, % of -9.92
- Positive: Shareholder equity ratio, % of 79.23 > 63.39
- Positive: Interest expense per share per price, % of 0.63 <= 0.79
- Positive: Inventory ratio change, % of -8.58 <= -0.75
- Positive: 0.33 < Operating cash flow per share per price, % of 3.03
Short-term CTKB quotes
Long-term CTKB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $164.04MM | $193.01MM | $200.45MM |
| Operating Expenses | $165.84MM | $220.86MM | $220.98MM |
| Operating Income | $-1.80MM | $-27.84MM | $-20.52MM |
| Non-Operating Income | $3.06MM | $12.14MM | $14.82MM |
| Interest Expense | $2.57MM | $2.07MM | $5.24MM |
| R&D Expense | $34.86MM | $44.15MM | $39.40MM |
| Income(Loss) | $1.26MM | $-15.71MM | $-5.70MM |
| Taxes | $-1.22MM | $-3.56MM | $0.32MM |
| Profit(Loss)* | $2.58MM | $-12.15MM | $-6.02MM |
| Stockholders Equity | $425.55MM | $393.06MM | $395.74MM |
| Inventory | $48.15MM | $60.88MM | $43.89MM |
| Assets | $519.48MM | $494.46MM | $499.50MM |
| Operating Cash Flow | $-12.23MM | $5.28MM | $25.38MM |
| Capital expenditure | $9.87MM | $4.83MM | $3.52MM |
| Investing Cash Flow | $-55.91MM | $-93.89MM | $-82.97MM |
| Financing Cash Flow | $5.51MM | $-41.81MM | $-15.82MM |
| Earnings Per Share** | $0.02 | $-0.09 | $-0.05 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.